Advertisement
Home »

Upadacitinib: A Novel Treatment Possibility for Vitiligo

Mar 19, 2024

REFERENCES & ADDITIONAL READING

Passeron T. Efficacy and safety after 52 weeks of once-daily upadacitinib in adults with extensive non-segmental vitiligo (NSV): final results from a phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Presented at: AAD 2024 Annual Meeting, March 8-12, 2024, San Diego, USA.

ABOUT THE CONTRIBUTORS

Author

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


EXPLORE MORE

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement